Molnupiravir May Be Triggering Covid Mutations; New FDA Guidance On Antibiotics In Food Animals
Read recent pharmaceutical developments in KFF Health News' Prescription Drug Watch roundup.
CIDRAP:
Scientists Detail Link Between Molnupiravir And SARS-CoV-2 Mutations
A new paper suggests scientists are worried about molnupiravir's capacity to trigger SARS-CoV-2 mutations, echoing concerns that were raised even before countries approved it for emergency use in late 2021 as the Omicron variant arrived on the scene. (Schnirring, 9/26)
CIDRAP:
FDA Releases Draft Guidance On Antibiotic Duration Limits In Food Animals
The US Food and Drug Administration (FDA) today published draft guidance for defining appropriate duration of use in antibiotics used in the feed of food-producing animals. (Dall, 9/26)
New England Journal of Medicine:
Dabrafenib Plus Trametinib In Pediatric Glioma With BRAF V600 Mutations
Detection of the BRAF V600E mutation in pediatric low-grade glioma has been associated with a lower response to standard chemotherapy. In previous trials, dabrafenib (both as monotherapy and in combination with trametinib) has shown efficacy in recurrent pediatric low-grade glioma with BRAF V600 mutations, findings that warrant further evaluation of this combination as first-line therapy. (Bouffet, M.D., et al, 9/21)
